

IIT Mandi links opioid addiction drug with type 2 diabetes

02 November 2020 | News

The researchers identified a critical protein molecule – SIRT1 which is repressed in hyperinsulinemia



Researchers from the Indian Institute of Technology (IIT) Mandi have unravelled the mechanism by which insulin overload in the body causes insulin resistance that is associated with diabetes. They have found the drug that is used in treating opioid addiction can potentially reverse this phenomenon.

The results of the research work that was funded by the Science & Engineering Research Board (SERB) grant, have recently been published in the Journal of Biological Chemistry. The paper has been authored by the lead scientist on this research Dr Prosenjit Mondal, Associate Professor, School of Basic Sciences, IIT Mandi, and Co-investigators on the study were research scholars, Abhinav Choubey, Khyati Girdhar of IIT Mandi along with Dr Debabrata Ghosh, Aditya K Kar, and Shaivya Kushwaha of CSIR-IITR, Lucknow and Dr Manoj Kumar Yadav of SRM University, Delhi-NCR, Sonipat, Haryana,

“We’ve known that one of the causes of insulin resistance is inflammation”, says Dr Mondal, “We wanted to find out if and how hyperinsulinemia invokes inflammation in the body, which would provide the link between the two conditions”.

The researchers identified a critical protein molecule – SIRT1 which is repressed in hyperinsulinemia. They discovered that a decrease in SIRT1 activates another protein called NFκB, which instigates inflammation, thus providing the link between hyperinsulinemia and systemic inflammation.

The team has also discovered a solution to this problem. The researchers found that low-dose naltrexone (LDN), a drug commonly administered for opiate addiction, can activate SIRT1, thereby reducing inflammation and increasing insulin

sensitivity of cells.

The significance of this discovery is enormous. “Naltrexone at low doses could potentially restore some of the diabetes-associated events in cellular and animal models”, says Dr Mondal, who is confident that this is a viable path to follow for Type-2 diabetes management. Naltrexone is already an FDA-approved drug that is used for the treatment of opioid addiction and can easily be repurposed for inflammation reduction and diabetes control. The research team intends to study this thread further, to understand the mechanistic aspects of LDN's effects on hyperinsulinemia-induced inflammation and resulting insulin resistance.

Image caption- (L to R) Dr Prosenjit Mondal, Associate Profesor, School of Basic Sciences, IIT Mandi, along with his research scholar Abhinav Choubey